Concepts (182)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunotherapy, Adoptive | 12 | 2025 | 888 | 2.440 |
Why?
|
| T-Lymphocytes | 16 | 2025 | 1814 | 2.180 |
Why?
|
| Receptor, ErbB-2 | 9 | 2025 | 559 | 2.090 |
Why?
|
| Glioblastoma | 8 | 2018 | 374 | 1.480 |
Why?
|
| Sarcoma | 3 | 2025 | 209 | 1.030 |
Why?
|
| Immunotherapy | 7 | 2021 | 746 | 0.990 |
Why?
|
| Interleukin-13 Receptor alpha2 Subunit | 4 | 2018 | 20 | 0.880 |
Why?
|
| Antigens, Neoplasm | 4 | 2020 | 407 | 0.860 |
Why?
|
| Receptors, Antigen, T-Cell | 8 | 2020 | 503 | 0.840 |
Why?
|
| Brain Neoplasms | 7 | 2020 | 1407 | 0.810 |
Why?
|
| Muscle Neoplasms | 1 | 2020 | 21 | 0.680 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2025 | 1313 | 0.650 |
Why?
|
| Cancer Vaccines | 3 | 2020 | 190 | 0.640 |
Why?
|
| Tumor Escape | 2 | 2016 | 65 | 0.610 |
Why?
|
| Rhabdomyosarcoma | 1 | 2020 | 209 | 0.550 |
Why?
|
| Cell- and Tissue-Based Therapy | 2 | 2017 | 170 | 0.530 |
Why?
|
| Adoptive Transfer | 2 | 2014 | 241 | 0.480 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2014 | 216 | 0.360 |
Why?
|
| Cell Line, Tumor | 6 | 2025 | 3751 | 0.360 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 4 | 2023 | 1188 | 0.350 |
Why?
|
| Hematologic Neoplasms | 2 | 2025 | 294 | 0.340 |
Why?
|
| Lymphocyte Activation | 2 | 2025 | 724 | 0.310 |
Why?
|
| Neoplasms | 4 | 2025 | 3025 | 0.290 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 1068 | 0.290 |
Why?
|
| Xenograft Model Antitumor Assays | 7 | 2025 | 1006 | 0.280 |
Why?
|
| Lymphocyte Depletion | 2 | 2024 | 125 | 0.270 |
Why?
|
| Transplantation Conditioning | 2 | 2018 | 300 | 0.250 |
Why?
|
| Endoglin | 1 | 2025 | 30 | 0.240 |
Why?
|
| Mice, SCID | 3 | 2018 | 613 | 0.240 |
Why?
|
| B7 Antigens | 1 | 2025 | 14 | 0.240 |
Why?
|
| Cyclophosphamide | 2 | 2024 | 417 | 0.230 |
Why?
|
| Antibodies, Bispecific | 1 | 2025 | 51 | 0.230 |
Why?
|
| Immunological Synapses | 1 | 2025 | 29 | 0.230 |
Why?
|
| Membrane Microdomains | 1 | 2025 | 63 | 0.220 |
Why?
|
| Humans | 31 | 2025 | 133414 | 0.220 |
Why?
|
| Vidarabine | 1 | 2024 | 78 | 0.220 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2025 | 116 | 0.220 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2025 | 129 | 0.220 |
Why?
|
| B7-H1 Antigen | 1 | 2025 | 129 | 0.220 |
Why?
|
| Mice | 9 | 2025 | 18911 | 0.210 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2023 | 46 | 0.200 |
Why?
|
| Antigens, CD19 | 2 | 2021 | 181 | 0.190 |
Why?
|
| Tumor Cells, Cultured | 4 | 2020 | 1102 | 0.190 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2022 | 358 | 0.190 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2025 | 551 | 0.180 |
Why?
|
| Leukemia | 1 | 2024 | 380 | 0.180 |
Why?
|
| Treatment Outcome | 6 | 2024 | 12974 | 0.170 |
Why?
|
| Lymphoma | 1 | 2024 | 335 | 0.170 |
Why?
|
| Child | 14 | 2025 | 25734 | 0.170 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2020 | 66 | 0.170 |
Why?
|
| Leukemia, B-Cell | 1 | 2020 | 26 | 0.170 |
Why?
|
| Animals | 10 | 2025 | 36379 | 0.170 |
Why?
|
| Cerebrospinal Fluid | 1 | 2020 | 99 | 0.160 |
Why?
|
| Transplantation, Autologous | 1 | 2020 | 285 | 0.160 |
Why?
|
| Immunologic Memory | 1 | 2021 | 199 | 0.160 |
Why?
|
| Remission Induction | 1 | 2020 | 307 | 0.160 |
Why?
|
| Transgenes | 2 | 2020 | 346 | 0.150 |
Why?
|
| Osteosarcoma | 2 | 2019 | 263 | 0.150 |
Why?
|
| Bone Marrow | 1 | 2020 | 335 | 0.150 |
Why?
|
| Receptor, EphA2 | 1 | 2018 | 29 | 0.150 |
Why?
|
| Ependymoma | 1 | 2020 | 175 | 0.150 |
Why?
|
| Epigenomics | 1 | 2019 | 195 | 0.140 |
Why?
|
| Antigenic Variation | 1 | 2018 | 42 | 0.140 |
Why?
|
| Wiskott-Aldrich Syndrome | 1 | 2017 | 23 | 0.140 |
Why?
|
| Alemtuzumab | 1 | 2018 | 88 | 0.140 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 2018 | 69 | 0.140 |
Why?
|
| Male | 13 | 2025 | 65692 | 0.130 |
Why?
|
| Biopsy | 1 | 2020 | 1300 | 0.130 |
Why?
|
| Transplantation, Homologous | 1 | 2018 | 692 | 0.130 |
Why?
|
| Protein Binding | 2 | 2020 | 1833 | 0.130 |
Why?
|
| Interleukin-13 | 1 | 2016 | 101 | 0.130 |
Why?
|
| Prospective Studies | 2 | 2024 | 6570 | 0.120 |
Why?
|
| Protein Multimerization | 1 | 2016 | 144 | 0.120 |
Why?
|
| Neoplasm Transplantation | 1 | 2016 | 399 | 0.120 |
Why?
|
| HEK293 Cells | 2 | 2020 | 813 | 0.120 |
Why?
|
| Autoimmune Diseases | 1 | 2018 | 276 | 0.120 |
Why?
|
| Flow Cytometry | 2 | 2015 | 836 | 0.120 |
Why?
|
| Microspheres | 1 | 2015 | 75 | 0.120 |
Why?
|
| Receptors, Cell Surface | 1 | 2017 | 497 | 0.120 |
Why?
|
| Immediate-Early Proteins | 1 | 2015 | 60 | 0.120 |
Why?
|
| Viral Matrix Proteins | 1 | 2015 | 110 | 0.120 |
Why?
|
| Medulloblastoma | 1 | 2020 | 570 | 0.120 |
Why?
|
| Head and Neck Neoplasms | 1 | 2021 | 699 | 0.120 |
Why?
|
| Female | 14 | 2025 | 71463 | 0.120 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2021 | 872 | 0.110 |
Why?
|
| Child, Preschool | 8 | 2025 | 14789 | 0.110 |
Why?
|
| Immunophenotyping | 1 | 2015 | 342 | 0.110 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2017 | 267 | 0.110 |
Why?
|
| Follow-Up Studies | 5 | 2025 | 5455 | 0.110 |
Why?
|
| Adenocarcinoma | 1 | 2021 | 1070 | 0.110 |
Why?
|
| Adolescent | 9 | 2025 | 20505 | 0.100 |
Why?
|
| Neoplasm Proteins | 1 | 2017 | 716 | 0.100 |
Why?
|
| Adult | 7 | 2024 | 31787 | 0.100 |
Why?
|
| Phosphoproteins | 1 | 2015 | 456 | 0.100 |
Why?
|
| Cardiovascular Diseases | 1 | 2025 | 2087 | 0.090 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2025 | 277 | 0.090 |
Why?
|
| Aged | 4 | 2024 | 21609 | 0.090 |
Why?
|
| Maximum Tolerated Dose | 2 | 2025 | 173 | 0.090 |
Why?
|
| Genomics | 1 | 2019 | 1672 | 0.090 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2018 | 809 | 0.090 |
Why?
|
| Infant | 6 | 2025 | 13159 | 0.090 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2013 | 801 | 0.080 |
Why?
|
| Bone Neoplasms | 1 | 2015 | 446 | 0.080 |
Why?
|
| Antigens, Viral | 1 | 2012 | 440 | 0.080 |
Why?
|
| Middle Aged | 4 | 2024 | 29213 | 0.080 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 1306 | 0.080 |
Why?
|
| Cytomegalovirus | 3 | 2017 | 270 | 0.080 |
Why?
|
| Models, Biological | 1 | 2013 | 1532 | 0.070 |
Why?
|
| Retrospective Studies | 5 | 2025 | 17380 | 0.070 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 1787 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 1850 | 0.060 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2025 | 26 | 0.060 |
Why?
|
| Neoplasm Metastasis | 2 | 2020 | 745 | 0.060 |
Why?
|
| Pediatrics | 1 | 2014 | 1216 | 0.060 |
Why?
|
| CD28 Antigens | 1 | 2025 | 81 | 0.060 |
Why?
|
| Young Adult | 3 | 2025 | 9854 | 0.050 |
Why?
|
| Busulfan | 1 | 2023 | 45 | 0.050 |
Why?
|
| Neutropenia | 1 | 2024 | 201 | 0.050 |
Why?
|
| Survival Rate | 2 | 2017 | 2210 | 0.050 |
Why?
|
| Thrombocytopenia | 1 | 2024 | 236 | 0.050 |
Why?
|
| Prognosis | 2 | 2025 | 5074 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2025 | 1734 | 0.050 |
Why?
|
| Apoptosis | 2 | 2018 | 1928 | 0.040 |
Why?
|
| Injections, Intraventricular | 1 | 2020 | 65 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2018 | 2548 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2021 | 217 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2021 | 215 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2021 | 364 | 0.040 |
Why?
|
| Transduction, Genetic | 1 | 2020 | 296 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2020 | 610 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2020 | 232 | 0.040 |
Why?
|
| Gene Editing | 1 | 2021 | 212 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2021 | 445 | 0.040 |
Why?
|
| Chimerism | 1 | 2018 | 29 | 0.040 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2018 | 31 | 0.040 |
Why?
|
| Pancytopenia | 1 | 2018 | 42 | 0.040 |
Why?
|
| Unrelated Donors | 1 | 2018 | 70 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2018 | 318 | 0.030 |
Why?
|
| Allografts | 1 | 2017 | 198 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2018 | 275 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 1154 | 0.030 |
Why?
|
| Mutation | 2 | 2021 | 6290 | 0.030 |
Why?
|
| Cerebellar Neoplasms | 1 | 2020 | 461 | 0.030 |
Why?
|
| Polystyrenes | 1 | 2015 | 12 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2017 | 289 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2019 | 8586 | 0.030 |
Why?
|
| Color | 1 | 2015 | 34 | 0.030 |
Why?
|
| Neuroectodermal Tumors | 1 | 2015 | 13 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 971 | 0.030 |
Why?
|
| Gene Expression | 1 | 2020 | 1614 | 0.030 |
Why?
|
| Proteomics | 1 | 2019 | 595 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 791 | 0.030 |
Why?
|
| Interleukin-13 Receptor alpha1 Subunit | 1 | 2014 | 6 | 0.030 |
Why?
|
| Adenoviridae | 1 | 2017 | 610 | 0.030 |
Why?
|
| Immunotoxins | 1 | 2014 | 21 | 0.030 |
Why?
|
| Herpesvirus 4, Human | 1 | 2017 | 675 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2020 | 2526 | 0.030 |
Why?
|
| Leukocytes | 1 | 2015 | 223 | 0.030 |
Why?
|
| Fluorescent Dyes | 1 | 2015 | 270 | 0.030 |
Why?
|
| Sarcoma, Ewing | 1 | 2015 | 116 | 0.030 |
Why?
|
| Antibodies | 1 | 2015 | 382 | 0.030 |
Why?
|
| Cytokines | 1 | 2020 | 1393 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 310 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2014 | 412 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2025 | 4897 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 1139 | 0.020 |
Why?
|
| Cell Separation | 1 | 2012 | 234 | 0.020 |
Why?
|
| Recurrence | 1 | 2015 | 1464 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2012 | 484 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2014 | 1437 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2017 | 3642 | 0.020 |
Why?
|
| Biomarkers | 1 | 2020 | 3424 | 0.020 |
Why?
|
| Incidence | 1 | 2018 | 3396 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 866 | 0.020 |
Why?
|
| Cytomegalovirus Infections | 1 | 2012 | 228 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2017 | 1717 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 4779 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 2172 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2014 | 2120 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2015 | 5176 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 3840 | 0.010 |
Why?
|
| Risk Factors | 1 | 2017 | 11085 | 0.010 |
Why?
|